Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
Clinical trial NCT03697824 · WITHDRAWN
Trial details
- NCT number
- NCT03697824
- Sponsor
- GlaxoSmithKline
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-25
- Primary completion
- 2022-07-18
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.